Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

Zoltán Bánki(Innsbruck Medical University), Janine Kimpel(Innsbruck Medical University), Lisa Seekircher, Hanno Ulmer(Innsbruck Medical University), Michael Kundi(Medical University of Vienna), Annika Rössler(Beth Israel Deaconess Medical Center), Peter Willeit(Innsbruck Medical University), Alessandro Sette(La Jolla Institute for Immunology), Helena Schäfer(Innsbruck Medical University), Lukas Forer(Innsbruck Medical University), Marton Széll(La Jolla Institute for Immunology), Lydia Riepler(Innsbruck Medical University), Elisabeth Graf(Helmholtz Zentrum München), Dorotheé von Laer(Innsbruck Medical University), Ursula Wiedermann(Medical University of Vienna), Bianca Neurauter(Innsbruck Medical University), José Mateus(Pontificia Universidad Javeriana), Magdalena Sacher, Reinhard Würzner(Universität Innsbruck), Florian Krammer(Semmelweis University), Daniela Weiskopf(Federal Office for Radiation Protection), Peter Heininger, Daniel N. Rainer(Charles University), David Bante(Innsbruck Medical University), Alba Grifoni(La Jolla Institute for Immunology), August Zabernigg, Tobias Trips, Petra Flatscher(Icahn School of Medicine at Mount Sinai), Gerhard Hausberger(Innsbruck Medical University), Christine Mantinger, Conny Ower, Viviana Simon(Icahn School of Medicine at Mount Sinai), Wegene Borena(Innsbruck Medical University), Sebastian Schönherr(University Hospital Leipzig), Barbara Falkensammer(Innsbruck Medical University)
EBioMedicine
May 23, 2022
Cited by 38


Related Papers